Cost of hospital treatment of type 1 diabetes (T1DM) and type 2 diabetes (T2DM) compared to the non-diabetes population: a detailed economic evaluation.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
05 05 2020
Historique:
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 16 2 2021
Statut: epublish

Résumé

Other than age, diabetes is the largest contributor to overall healthcare costs and reduced life expectancy in Europe. This paper aims to more exactly quantify the net impact of diabetes on different aspects of healthcare provision in hospitals in England, building on previous work that looked at the determinants of outcome in type 1 diabetes (T1DM) and type 2 diabetes (T2DM). NHS Digital Hospital Episode Statistics (HES) in England was combined with the National Diabetes Audit (NDA) to provide the total number in practice of people with T1DM/T2DM. We compared differences between T1DM/T2DM and non-diabetes individuals in relation to hospital activity and associated cost. The study captured 90% of hospital activity and £36 billion/year of hospital spend. The NDA Register showed that out of a total reported population of 58 million, 2.9 million (6.5%) had T2DM and 240 000 (0.6%) had T1DM. Bed-day analysis showed 17% of beds are occupied by T2DM and 3% by T1DM. The overall cost of hospital care for people with diabetes is £5.5 billion/year. Once the normally expected costs including the older age of T2DM hospital attenders are allowed for this fell to £3.0 billion/year or 8% of the total captured secondary care costs. This equates to £560/non-diabetes person compared with £3280/person with T1DM and £1686/person with T2DM. For people with diabetes, the net excess impact on non-elective/emergency work is £1.2 billion with additional estimated diabetes-related accident & emergency attendances at 440 000 costing the NHS £70 million/year. T1DM individuals required five times more secondary care support than non-diabetes individuals. T2DM individuals, even allowing for the age, require twice as much support as non-diabetes individuals. This analysis shows that additional cost of provision of hospital services due to their diabetes comorbidities is £3 billion above that for non-diabetes, and that within this, T1DM has three times as much cost impact as T2DM. We suggest that supporting patients in diabetes management may significantly reduce hospital activity.

Identifiants

pubmed: 32376746
pii: bmjopen-2019-033231
doi: 10.1136/bmjopen-2019-033231
pmc: PMC7223153
doi:

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e033231

Informations de copyright

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Diabet Med. 2012 Jun;29(6):807-12
pubmed: 22132868
Diabetes Care. 2009 Aug;32(8):1453-8
pubmed: 19435958
Diabet Med. 2018 Jan;35(1):63-71
pubmed: 29120503
Diabet Med. 2012 Jul;29(7):855-62
pubmed: 22537247
Diabetes Res Clin Pract. 2012 Nov;98(2):236-42
pubmed: 23084281
Diabetes Obes Metab. 2018 Jan;20(1):185-194
pubmed: 28730750
Clin Diabetes Endocrinol. 2017 Aug 15;3:7
pubmed: 28824815
BMJ. 2010 Aug 20;341:c4093
pubmed: 20729270
BMJ. 2008 Mar 1;336(7642):491-5
pubmed: 18276664
Diabet Med. 2004 May;21(5):460-7
pubmed: 15089791

Auteurs

Mike Stedman (M)

Health Research, Res Consortium, Andover, UK.

Mark Lunt (M)

ARC Epidemiology Unit, University of Manchester, Manchester, UK.

Mark Davies (M)

Health Research, Res Consortium, Andover, UK.

Mark Livingston (M)

Clinical Biochemistry, Walsall Healthcare NHS Trust, Walsall, Walsall, UK.

Christopher Duff (C)

Department of Clinical Biochemistry, University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, Staffordshire, UK.

Anthony Fryer (A)

Institute for Science & Technology in Medicine, Keele University, Stoke on Trent, UK.

Simon George Anderson (SG)

The George Alleyne Chronic Disease Research Centre, University of the West Indies Cave Hill Campus, Bridgetown, Saint Michael, Barbados.

Roger Gadsby (R)

Medical School, University of Warwick, Coventry, Coventry, UK.

Martin Gibson (M)

Endocrinology and Diabetes, Salford Royal Hospital, Salford, UK.

Gerry Rayman (G)

The Ipswich Diabetes Centre and Research Unit, Ipswich Hospital NHS Trust, Colchester, Essex, UK.

Adrian Heald (A)

Department of Endocrinology and Diabetes, Salford Royal Hospital, Salford, UK adrian.heald@manchester.ac.uk.
Faculty of Biology, Medicine & Health, and Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH